Submitted by Anonymous (not verified) on 29 November 2023 - 14:00
Human medicines European public assessment report (EPAR): Blitzima, rituximab, Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 13/07/2017, Revision: 19, Status: Authorised
Source: